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Abstract
Risk-taking behaviour is an important component of several psychiatric disorders, including attention-deﬁcit
hyperactivity disorder, schizophrenia and bipolar disorder. Previously, two genetic loci have been associated with self-
reported risk taking and signiﬁcant genetic overlap with psychiatric disorders was identiﬁed within a subsample of UK
Biobank. Using the white British participants of the full UK Biobank cohort (n= 83,677 risk takers versus 244,662
controls) for our primary analysis, we conducted a genome-wide association study of self-reported risk-taking
behaviour. In secondary analyses, we assessed sex-speciﬁc effects, trans-ethnic heterogeneity and genetic overlap with
psychiatric traits. We also investigated the impact of risk-taking-associated SNPs on both gene expression and
structural brain imaging. We identiﬁed 10 independent loci for risk-taking behaviour, of which eight were novel and
two replicated previous ﬁndings. In addition, we found two further sex-speciﬁc risk-taking loci. There were strong
positive genetic correlations between risk-taking and attention-deﬁcit hyperactivity disorder, bipolar disorder and
schizophrenia. Index genetic variants demonstrated effects generally consistent with the discovery analysis in
individuals of non-British White, South Asian, African-Caribbean or mixed ethnicity. Polygenic risk scores comprising
alleles associated with increased risk taking were associated with lower white matter integrity. Genotype-speciﬁc
expression pattern analyses highlighted DPYSL5, CGREF1 and C15orf59 as plausible candidate genes. Overall, our
ﬁndings substantially advance our understanding of the biology of risk-taking behaviour, including the possibility of
sex-speciﬁc contributions, and reveal consistency across ethnicities. We further highlight several putative novel
candidate genes, which may mediate these genetic effects.
Introduction
The Research Domain Criteria approach proposes
studying traits existing in the general population (rather
than categorical diagnoses) to better understand psycho-
pathology. One such trait is risk-taking behaviour, a key
component of psychiatric disorders such as attention-
deﬁcit hyperactivity disorder (ADHD)1,2 and bipolar dis-
order (BD)3. Risk taking is also observed in schizophrenia
(SCZ), although cognitive difﬁculties4,5 may confound this
relationship. Problem behaviours such as smoking and
drug and alcohol misuse6,7 frequently co-occur with
psychiatric disorders and might also be considered a
consequence of risk-taking behaviour.
Previous studies have found that risk taking and
impulsivity are associated with reduced grey matter
volumes and/or reduced thickness in several subcortical
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and prefrontal regions of the brain, as well as with
reduced white matter integrity8–10. It is therefore likely
that genetic predisposition to risk-taking behaviour
impacts on brain structure and function.
Previous genetic studies of risk taking11–13 identiﬁed
two associated loci (CADM2 (cell adhesion molecule 2)
and a locus within the HLA (human leukocyte antigen)
region) and found genetic correlations with ADHD, BD
and SCZ, smoking, alcohol and drug use13. The full UK
Biobank data release more than doubles the sample size
available for genome-wide association studies (GWAS)
of risk taking and allows for the investigation of sex-
speciﬁc effects, the assessment of trans-ethic hetero-
geneity, and assessment of genetic effects on brain
structures.
Subjects and methods
UK Biobank and primary phenotype deﬁnition
UK Biobank is a population cohort of over 0.5 million
individuals recruited between 2006 and 201014. Baseline
assessments included extensive questionnaires on
socioeconomic status, lifestyle and medical history. All
participants provided informed consent. This study was
carried out under the generic approval from the NHS
National Research Ethics Service (Ref 16/NW/0274) and
under UK Biobank applications #6553 and #17689.
Genotyping, imputation and quality control procedures
have been described previously15–18 (Supplemental
Information). Self-reported risk-taking behaviour was
assessed with the question: “Would you describe your-
self as someone who takes risks?” (data ﬁeld #2040).
Individuals who responded “no” are here referred to as
controls (n= 244,662) and those who responded “yes”
are “risk takers” (n= 83,677). Assessment of response
consistency was possible for a subset of participants (n
= 14,551) who answered the same question at follow-up
(during 2012–2013). Figure 1 demonstrates the study
design.
GWAS of self-reported risk-taking behaviour
For the GWAS, only participants of (self-reported)
white British ancestry were analysed (including those
analysed in our previous study13, Fig. 1 and Supplemental
Information). Logistic regression was conducted in
PLINK 1.0719 assuming additive allelic effects. Analyses
were conducted initially in all subjects and subsequently
stratiﬁed by sex, adjusting for age, genotyping chip and
population structure (using eight principal components)
and sex (combined analysis only). The threshold for
GWAS signiﬁcance was set at p < 5 × 10−8. Linkage dis-
equilibrium score regression (LDSR)20 was used to esti-
mate the risk-taking single nucleotide polymorphism
(SNP) heritability (h2SNP, observed scale).
Genetic correlations with related traits
Genetic correlations between risk-taking behaviour and
published GWAS summary statistics of psychiatric, cog-
nitive and behavioural traits were investigated using
LDSR20. A small number of phenotypes for LDSR were
chosen based on a priori biological and clinical knowledge,
so no multiple testing correction was applied and p < 0.05
was considered signiﬁcant (Supplemental Information).
Phenotypes assessed: ADHD, post-traumatic stress dis-
order (PTSD), BD, SCZ, major depressive disorder (MDD),
anxiety, ﬂuid intelligence, years of education, lifetime
cannabis use, ever smoking, alcohol consumption, body
mass index (BMI), waist to hip ratio adjusted for BMI
(WHRadjBMI), caudate and accumbens volumes.
Genetic analysis of lead SNPs in all ethnicities
To assess whether associated loci were consistent across
different ethnicities, the effects of lead SNPs on risk-
taking behaviour were also assessed in individuals of self-
reported south Asian (n= 2764 risk takers versus 4267
controls), African-Caribbean (n= 3139 versus 4341),
white non-British (n= 16,169 versus 31,814) and mixed
ethnicity (n= 3866 versus 5988) backgrounds (Fig. 1).
Genetic analysis was conducted in PLINK19 as above. An
UK Biobank
N=502,000
GWAS
White Brish 
(Including 
N=116255 from 
Strawbridge 
et al 2018)
N=328339
MRI
White Brish 
n=8535 (87.8%)
White non-
Brish N=1190 
(12.2%)
South Asian 
N=61 (0.6%)
African 
Caribbean N=91 
(0.9%)
Mixed 
N=129 (1.2%)
Trans-ethnic 
analyses
White non-Brish
N=47983 
South Asian
N=7031 
African Caribbean
N=7480
Mixed
N=9854
Genec exclusions 
quality control failure, 
relatedness, sex mismatch 
Relatedness exclusions
one individual from each pair of related 
individuals was included
Fig. 1 Flow diagram outlining the study design. Primary analysis
included all white British participants, whereas secondary analysis
included trans-ethnic assessment of the risk-taking loci
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inverse variance-weighted meta-analysis of all ethnic
groups was conducted in METAL21 to measure hetero-
geneity in effects across the ethnic groups.
Polygenic risk score analyses and magnetic resonance
imaging (MRI)
The subset of UK Biobank individuals who had brain
MRI data were examined to assess the impact of a poly-
genic risk score (PRS) for risk taking on measures of white
matter integrity, total tissue volumes and volumes of
selected anatomical regions of interest (ROIs) previously
been implicated in risk-taking behaviour (Fig. 1, Supple-
mental Information). The PRS was calculated using
summary statistics from a secondary GWAS in which
participants with MRI data had been excluded.
MRI analyses
Details of the MRI procedure in UK Biobank have been
described previously22 and are presented in the Supple-
mental Information. In brief, brain MRI scanning was
conducted at a single site, and structural T1 and DTI
measures were calculated by UK Biobank, using FSL
(FMRIB Software Library)23.
Based on a literature search (Supplemental Informa-
tion), associations between PRS and structural MRI
volumes of 10 anatomical ROIs were assessed. PRS
associations with white matter integrity were also exam-
ined, because of prior publications of associations
between diffusion tensor imaging (DTI) metrics and
measures of risk taking or impulsivity10,24. Anatomical
ROIs analysed were middle frontal gyrus, amygdala,
orbitofrontal cortex, anterior cingulate, insular cortex,
caudate, hippocampus, supra-marginal gyrus, nucleus
accumbens and putamen. PRS were divided into quin-
tiles25, and for each MRI outcome the top and bottom
20% were compared using linear regression/linear mixed
model with hemisphere as a ﬁxed factor (Supplemental
Information). MRI outcomes were standardised so results
reﬂect standard deviation change. After exclusion of
participants who self-reported a neurological disorder at
either the baseline assessment or imaging visit (n= 683,
6.9%) (Table S2), there were 9249 individuals with PRS
and MRI measurements available for analysis.
Expression quantitative trait locus analysis
The lead SNP from each locus was assessed for the
possibility of genotype-speciﬁc gene expression patterns
(or expression quantitative trait loci, eQTLs) in dorso-
lateral prefrontal cortex (DLPFC) using the Lieber Insti-
tute for Brain Development (LIBD) RNA-Seq data,
accessed via the eQTL Browser26. For SNPs showing
signiﬁcant eQTLs in the LIBD dataset, we looked for
replication in the CommonMind Consortium (CMC)
DLPFC RNA-Seq data (n= 547)27, using the LIBD eQTL
Browser. eQTLs that reached a threshold of α= 0.05 in
the LIBD dataset (false discovery rate (FDR)-corrected)
and replicated (deﬁned as a threshold of α= 0.05 in the
same direction) in the CMC dataset are reported. Tissue-
speciﬁc expression patterns were assessed for implicated
genes using the GTEx portal28 and the neurodevelop-
mental trajectories of implicated genes were assessed in
the BrainCloud dataset29.
Data mining
SNPs meeting the threshold for suggestive evidence of
association (p < 1 × 10−5) were assessed for potential
functional impact using the Variant Effect Predictor30. For
each SNP, only the most severe consequence (https://
www.ensembl.org/info/genome/variation/predicted_data.
html) was considered. Lead SNPs and the locus (500 kb up
and downstream of the lead SNPs) were queried using the
GWAS catalogue. Psychiatric and metabolic phenotypes
were reported.
Results
Demographic characteristics are presented in Table S1.
Risk takers were younger, more often men, more often
current or ever-smokers, and more likely to report mood
instability, a history of addiction or a history of mood
disorders13. They were also more likely to have a uni-
versity degree than controls13. As with our previous
report13, test–retest reliability was 84.4% (inconsistent
13.2%, missing 2.4%, n= 14,551).
The risk-taking GWAS of white British participants
identiﬁed 1162 genome-wide signiﬁcant SNPs at 10 loci
(Fig. 2a and Table S3), including the previously reported
CADM2 and HLA loci13.
Association of two previously reported loci with self-
reported risk taking
The CADM2 locus on Chr3 (85Mb) contained 812
GWAS-signiﬁcant SNPs (Fig. 3a and Table S3), including
a novel lead SNP (rs542809491) and the previously
reported lead SNP for risk taking, rs1308453113. Condi-
tional analysis including the previous lead SNP
(rs13084531) as a covariate had limited impact on the
effect size of the new lead SNP (rs542809491) and did not
remove the signiﬁcance of the association (Table S4).
Including rs542809491 as a covariate rendered the pre-
vious lead SNP nonsigniﬁcant. Indeed, after conditioning
on rs542809491, no SNPs in this locus reached even
suggestive association (p < 1 × 10−5), indicating that this
locus contains only one signal.
On Chr6, signiﬁcant SNPs were identiﬁed at 27Mb and
at 29Mb (Figs. 3b, c and Table S3). As these fall within
the extended HLA region, known to have extensive link-
age disequilibrium (LD), conditional analysis was con-
ducted on the two sets of SNPs together. The previous
Strawbridge et al. Translational Psychiatry  (2018) 8:178 Page 3 of 11
Fig. 2 Genome-wide associations with risk-taking behaviour. Manhattan plots of association with risk-taking behaviour (inset QQ plot) for a all
White British individuals, b White British men and c White British women
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lead SNP in this region failed to meet the suggestive level
of signiﬁcance here (rs9379971, p= 4.94 × 10−5). Condi-
tional analysis using this SNP increased the p of all SNPs
in the region somewhat whereas conditioning on either
the 27Mb lead SNP (rs188973463) or the 29Mb lead SNP
(rs566858049) attenuated all associations (Table S5).
Thus, this locus also appears to contain only one signal
(index SNP rs188973463).
Eight novel loci associated with self-reported risk taking
were identiﬁed
Eight novel risk-taking-associated loci were identiﬁed
(Table S3 and Figs. 3d–k). Conditional analyses demon-
strated that only the Chr3 (181Mb) locus was suggestive
of a second signal (Table S6). To aid data mining,
rs727644 (instead of 7:114156758 _GT_G) and
rs10895735 (instead of 11:104700736 _ACTTCAC_A)
were used as the lead SNPs of the loci on Chr7 and Chr11,
respectively, based on minor allele frequency (MAF)
similarity and nonsigniﬁcance in the conditional analyses.
Two sex-speciﬁc loci were identiﬁed
Compared with the previous GWAS of risk-taking
behaviour, the cohort size was more than doubled,
allowing for well-powered sex-speciﬁc analyses. The
characteristics of the sex-speciﬁc samples were com-
parable with the sex-combined samples (Table S7). In
men, two GWAS-signiﬁcant loci were identiﬁed (Fig. 2b,
Table S3). The CADM2 locus was the same as was
identiﬁed in the sex-combined analysis, albeit 100 kb
away, whereas the Chr12 locus (Fig. 3l) was unique to
men and did not reach even suggestive signiﬁcance (p <
1 × 10−5) in the sex-combined analysis. The women-
only analysis identiﬁed ﬁve loci (Fig. 2c and Table S3).
The lead SNPs at the CADM2 and CYP7B1 loci were the
same as for the sex-combined analysis. The lead SNPs
for the Chr1 (AKT3), Chr15 (C15orf59) and Chr10 locus
(speciﬁc to women) all reached suggestive evidence of
association in the sex-combined analysis. The condi-
tional analysis demonstrated that the women-only lead
SNP of the C15orf59 locus represented the same signal
as the sex-combined analysis (conditional p= 0.2234).
However, for the AKT3 signal the results were incon-
clusive (conditional p= 3.5 × 10−4). The women-speciﬁc
Chr10 locus lies within a gene desert (no coding genes
within a ﬂanking region of 500 kb up or downstream of
the lead SNP) (Fig. 3m).
Fig. 3 Regional plots of known loci: a CADM2, b, c extended HLA region; novel loci d AKT3, e KHK, f SOX2, g FOXP2, h CYP17B1, i CASP12, j C15orf59,
k NFAT5; and sex-speciﬁc loci l SOX5 and m Chr10 gene desert
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Genetic overlap with psychiatric, behavioural and
cognitive traits
LDSR demonstrated signiﬁcant genetic overlap between
self-reported risk taking and ADHD, SCZ, BD, MDD,
PTSD, smoking, alcohol consumption and cannabis use,
as well as with IQ (ﬂuid intelligence) and BMI (Table 1).
This is consistent with our previous report13.
Consistency of associations in other ethnicities
The demographic characteristics of non-British White,
South Asian, African-Caribbean and mixed ethnicities are
presented in Table S8. Overall, when assessing con-
sistency of effects across ethnicities, self-reported risk
takers were more often men and more likely to be smo-
kers and more often reported mood instability, history of
addiction and mood disorders. The effect of the lead SNPs
on risk taking in these ethnicities are presented in Table
S9. In white non-British individuals, the CADM2
(rs542809491), FOXP2 (rs727644) and CYP7B1
(rs189335278) loci demonstrated nominal signiﬁcance
with risk-taking behaviour. In South Asians, the SOX2
(rs9841382) and FOXP2 (rs727644) loci demonstrated
nominal signiﬁcance. No evidence of effects was observed
in African-Caribbean or mixed ethnicities. Meta-analysis
of all ethnicities demonstrated GWAS signiﬁcance (p <
5 × 10−8) for 8 of 11 loci (Table 2). Of these loci, six had
low heterogeneity (I2 was < 25%) and two had moderate
heterogeneity (I2 was 25% < 50%), consistent with failure
to detect effects in the separate ethnicities possibly being
due to sample size rather than lack of true effects.
Risk-taking PRS and brain imaging phenotypes
Multiple strategies were employed to explore the impact
of risk-taking SNPs on brain biology. One was to examine
whether the genetic variants inﬂuenced the structure of
brain regions previously implicated in risk-taking beha-
viours. Results of a secondary GWAS excluding the MRI
subset were consistent with those for the discovery
GWAS (Figure S2). Demographic characteristics of the
MRI subset (Fig. 1) were generally comparable with the
full cohort (Table S10), although there was enrichment
for having a university degree and higher afﬂuence.
Each SNP had only a small effect, therefore we also
assessed the total genetic burden of all risk-taking loci
using PRS. As it is likely that many variants (not only
GWAS-signiﬁcant SNPs) have effects on the anatomical
ROIs, a variety of different p-value thresholds were
employed31. Comparing the top versus bottom PRS
quintile demonstrated that at some p-value thresholds,
higher PRS was associated with lower volume of grey
matter in the middle frontal gyrus and insular cortex
(Table S11), but not with lower total grey matter volume
or greater ventricular cerebrospinal ﬂuid volume (both
head size-normalised, Table S12). In addition, higher
PRSs were associated with greater mean diffusivity
(reﬂecting poorer white matter integrity, Table S13), but
Table 1 Genetic correlations of self-reported risk taking with psychiatric disorders and relevant other traits
Trait rg se z p h2 obs h2 obs se h2 int h2 int se gcov int gcov int se
ADHD 0.382 0.036 10.6047 2.83E-26 0.230 0.015 1.033 0.010 −0.005 0.007
PTSD 0.350 0.130 2.6952 0.0070 0.090 0.044 0.996 0.006 −0.001 0.005
BD 0.289 0.043 6.7072 1.98E-11 0.115 0.010 1.022 0.008 0.000 0.006
SCZ 0.250 0.026 9.5325 1.54E-21 0.249 0.010 1.036 0.011 −0.001 0.007
MDD 0.136 0.059 2.3215 0.0203 0.113 0.015 0.987 0.008 0.004 0.007
Anxiety (case–control) −0.005 0.090 −0.0538 0.9571 0.074 0.029 1.003 0.007 0.002 0.005
Fluid intelligence −0.154 0.032 −4.8381 1.31E-06 0.196 0.011 1.015 0.008 −0.004 0.005
Years of education 0.011 0.024 0.4646 0.6422 0.127 0.004 0.929 0.010 0.023 0.006
Lifetime cannabis use 0.428 0.069 6.2412 4.34E-10 0.091 0.016 0.999 0.007 −0.003 0.006
Ever smoker 0.292 0.050 5.8257 5.69E-09 0.074 0.007 0.999 0.006 −0.001 0.006
Alcohol (quantitative) 0.217 0.061 3.5338 4.10E-04 0.053 0.008 1.014 0.007 −0.005 0.006
BMI 0.076 0.025 3.0204 0.0025 0.139 0.007 0.643 0.010 −0.002 0.006
WHRadjBMI 0.054 0.031 1.7572 0.0789 0.093 0.007 0.854 0.010 −0.006 0.006
Caudate volume −0.003 0.056 −0.0572 0.9544 0.247 0.038 0.969 0.006 0.004 0.005
Accumbens volume −0.002 0.094 −0.0249 0.9801 0.084 0.037 0.981 0.006 0.004 0.005
MDD major depressive disorder, BD bipolar disorder, SCZ schizophrenia, ADHD attention-deﬁcit hyperactivity disorder, BMI body mass index, WHRadjBMI waist:hip
ratio adjusted for BMI, alcohol dependence DSM 5 criteria, rg regression coefﬁcient, se standard error of the regression coefﬁcient, p p-value for the regression analysis.
Bold indicates nominally signiﬁcant values (P<0.05)
Strawbridge et al. Translational Psychiatry  (2018) 8:178 Page 6 of 11
not with fractional anisotropy (FA). These ﬁndings were
echoed by tract-speciﬁc analyses, where higher PRS was
associated with greater MD in 9 out of 15 tracts (Table
S14) but not with FA in any single tract (Table S15).
Associations between the risk-taking PRS and MD but not
FA are indicative of the greater sensitivity of MD. It is
worth noting that PRS based on more relaxed p-value
thresholds can demonstrate signiﬁcance when the strin-
gent ones do not, as increasing numbers of SNPs included
in the more relaxed PRS contribute to increased genetic
information, as well as increased statistical power. These
structural MRI associations are tentative, therefore spec-
ulation as to their functional relevance is not warranted.
Gene expression analysis
Eight of the lead SNPs (Table 2) were present in the
LIBD dataset. Three of these showed robust eQTLs
(rs2304681, rs3943093 and rs17187323). Most strikingly,
the chromosome 2 lead SNP (rs2304681) is associated
with the expression of several nearby genes (Table S16).
The most numerous and statistically robust associations
are with CGREF1 (minimum FDR-corrected p= 3.4 ×
10−22), with prominent associations also seen for KHK (p
= 1.5 × 10−13) and DPYSL5 (p= 4.2 × 10−5). Intriguingly,
for both CGREF1 and KHK there is evidence that the SNP
may be associated with the expression of speciﬁc tran-
scripts, because the rs2304681 A allele (associated with
reduced risk taking) predicts increased expression of
certain junctions/transcript features but decreased
expression of others (Figure S4; Table S16). In contrast,
for DPYSL5, the rs2304681 A allele uniformly predicts
decreased expression (Table S16). CGREF1, KHK and
DPYSL5 are all expressed in brain (Figure S5). Notably, in
the case of CGREF1 and DPYSL5, the brain is the tissue in
which these genes are most abundantly expressed.
Two of the SNPs found to predict risk taking only in
women also showed eQTLs. The rs3943093 T allele
(associated with lower risk of risk taking, Chr1) predicted
increased expression of SDCCAG8 (p= 7.7 × 10−11). The
A allele of rs17187323 (associated with increased risk
taking) predicted lower expression of C15orf59 (p=
0.00014; Table S16).
All of the genes implicated in the eQTL analyses show
some expression in human brain (Figure S5). Notably, in
the case of CGREF1, DPYSL5 and C15orf59 expression in
the brain is particularly prominent, compared with other
tissues (Figure S5). Furthermore, all of the genes high-
lighted above show evidence of differential expression
across development: CGREF1, KHK and C15orf59 show
greater expression in adult brain than foetal brain,
whereas this pattern is reversed for DPYSL5 and
SDCCAG8.
Data mining
The predicted functional consequences of risk-taking-
associated SNPs (GWAS and suggestive signiﬁcance)
highlighted a number of missense variants with poten-
tially moderate impact on genes (Table S17). One variant
on Chr6 was predicted to have a high impact:
rs539861690-A is predicted to give rise to a premature
stop codon in ZKSCAN4. Conditional analysis of the Chr6
region demonstrates that adjusting for the Chr6 lead
SNPs rs188973463 and rs566858049 reduced the asso-
ciation of rs539861690 with risk taking to nonsigniﬁcant
(p= 0.2824) or nominal signiﬁcance (p= 0.0129) respec-
tively. This suggests that rs539861690 could be the
Table 2 Trans-ethnic meta-analysis of lead SNPs
CHR BP SNP Locus A1 A2 Freq1 FreqSE Effect StdErr P Direction Isqa ChiSqa Dfa Het P
1 243,812,368 rs560977020 AKT3 t c 0.66 0.07 0.034 0.005 3.15E-10 +++++ 0 0.40 4 0.9825
2 27,315,252 rs2304681 KHK a g 0.37 0.01 −0.028 0.005 1.27E-07 --++- 51.3 8.21 4 0.08403
3 85,617,378 rs542809491 CADM2 a t 0.39 0.04 0.053 0.005 4.38E-23 +++-+ 27.1 5.48 4 0.2412
3 181,408,124 rs9841382 SOX2 t c 0.84 0.08 −0.052 0.007 7.24E-13 ----- 41.1 6.79 4 0.1476
6 27,766,842 rs188973463 HLA t g 0.74 0.04 0.037 0.006 4.13E-09 ++--+ 13.7 4.63 4 0.3269
29,230,129 rs566858049 t c 0.60 0.05 0.031 0.005 7.24E-09 ++-++ 6.1 4.26 4 0.3722
7 114,156,758 7:114156758 FOXP2 g gt 0.64 0.01 0.041 0.005 6.29E-14 +++-+ 2.2 4.09 4 0.3938
8 65,508,415 rs189335278 CYP7B1 a t 0.11 0.01 −0.054 0.008 7.71E-11 ----+ 0 1.60 4 0.8088
11 104,700,736 11:104700736 CASP12 a acttcac 0.26 0.05 0.034 0.006 4.16E-08 +0+++ 24.9 5.33 4 0.2552
15 74,064,198 rs545973460 C15orf59 a g 0.34 0.03 0.028 0.005 3.66E-07 +-+++ 51.3 8.22 4 0.08382
16 69,550,486 rs145206681 NFAT5 t c 0.06 0.01 0.056 0.011 3.23E-07 ++-+- 29.2 5.65 4 0.227
Cohorts included White British, White non-British, South Asian, African-Carribean, mixed
P meta-analysis p-value, Isq measure of heterogeneity, het P heterogeneity p-value
aAnalysis of heterogeneity. Bold indicates genome-wide signiﬁcant values (P<5.00E-8)
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functional variant in this region but as no genotype-
speciﬁc expression patterns were identiﬁed for this SNP
functional studies are required to verify this.
None of the lead SNPs have previously been reported
to be associated with any trait in the GWAS catalogue
(2018-01-31). These risk-taking loci have previously
been associated with: educational attainment32, SCZ33,34
and PTSD35 (Chr1 locus); cognitive function36,37, edu-
cational attainment32,38, adiposity39–41 and alcohol
consumption42 (CADM2 locus); SCZ43,44 and ADHD45
(Chr6 locus); and sleep duration46 (FOXP2 locus). Of
the previously reported SNPs at these loci, 16 met the
threshold for “suggestive” evidence of association with
risk taking in this study (Table S18). Where the reported
data allowed comparison, results were as expected
(Table S18), with alleles, which increased risk of
SCZ33,34,43,44 associated with increased risk taking; the
allele for increased sleep duration46 associated with
reduced risk taking; and the allele for increased infor-
mation processing speed37 also associated with reduced
risk taking. In contrast, the association between alleles
for increased educational attainment32 and increased
risk taking may seem counter-intuitive but is consistent
with previous ﬁndings from UK Biobank (n~116,000)13.
The allele associated with waist circumference41 was
associated with increased risk taking, but the opposite
was observed for BMI39, (although the BMI study was in
a Japanese population39, whereas the risk-taking study
was in a European study, so ethnic-speciﬁc effects (in
regulation of BMI and/or risk taking) could be respon-
sible for this discrepancy).
Discussion
Examining the biology of risk-taking behaviour has the
potential to improve our understanding of the patho-
physiology of psychiatric disorders such as ADHD, SCZ
and BD, as well as problem behaviours such as drug and
alcohol misuse. We identiﬁed two known loci (CADM2
and HLA), eight novel loci and two additional sex-speciﬁc
loci associated with risk-taking behaviour. We observed
that there was little heterogeneity in genetic effects across
different ethnicities. We also identiﬁed signiﬁcant genetic
correlations between risk taking and several psychiatric
disorders and eQTL analyses highlighted a number of
potential candidate genes through which the SNPs might
inﬂuence risk-taking behaviour.
The results presented here are consistent with previous
(smaller) risk-taking GWAS13. The larger sample size
reported here clariﬁed that each of the known loci
(CADM2 and HLA) consisted of only one signal. Similarly,
genetic correlations with ADHD, SCZ, BD, PTSD,
smoking, use of cannabis, intelligence and BMI were
comparable to those reported previously13. The nine sig-
nals in eight novel loci demonstrated similar effect sizes to
those previously reported in UK Biobank and overlapped
with loci previously associated with SCZ, sleep duration,
alcohol consumption and processing speed (in the
expected direction) (Table S18). As with other complex
traits, the effects of the associated SNPs were modest
(BETA= 0.033–0.067) compared with the effect of sex
(BETA= 0.83) but comparable with the effect of age
(BETA= 0.021). That increased risk taking positively
associated with higher educational attainment was unex-
pected but is consistent with our previous report on risk
taking13. It has been shown that (in adolescence), risk
takers do not view their behaviour as risky47. Although we
do not know if this is also the case for the UK Biobank
participants, it would lead to underestimation (rather than
inﬂation) of the true effect. In addition, we acknowledge
that risk taking is based on a single question and it maybe
unclear what exactly is captured by this phenotype (cal-
culated versus impulsive risks for example), however, a
more detailed study of the psychometric structure of risk
taking supports the validity of our approach48. We cannot
exclude that collider bias49 arising from patterns of self-
selection into the UK Biobank cohort contributes to this
(it is noted that self-reported risk takers in UK Biobank
have an increased frequency of having a university degree
than controls).
The ﬁnding of limited heterogeneity across ethnicities
of these signals is preliminary, as the sample sizes are
signiﬁcantly smaller than that of the discovery analysis.
However, this ﬁnding is plausible. Given that risk taking is
likely to have serious evolutionary consequences, such
traits are likely to be less varied than those with lower
selection pressure.
Very recently, Clifton et al. published results from a
GWAS of risk-taking behaviour in the UK Biobank50.
They applied a different analysis strategy to the dataset
and phenotype used here limited the report to a sex-
combined genetic discovery experiment. By using all
white British and white non-British participants and
software enabling the inclusion of related individuals,
their study had a larger sample size (N= 436,236) and
identiﬁed of 26 signiﬁcant loci (including most of the loci
reported here). The Clifton et al. lead SNPs had p ≤ 0.0003
in our smaller and more homogeneous study (Table S19),
suggesting that sample size is likely the reason for the
identiﬁcation of additional signals. Conditional analyses
(including lead SNPs as covariates, Table S20) demon-
strated that the same loci were identiﬁed at loci on Chr2
(KHK/MAPRES2), 3 (SOX2 and CADM2), 7 (FOXP2), 8
(CYP7B1), 11 (CASP12/PDGFD). These analyses also
demonstrated that the loci reported on Chr6 (at 27 and
29Mb) likely contain the same signal. Trans-ethnic ana-
lysis of the Clifton et al. lead SNPs was consistent with our
analysis, with generally low heterogeneity for risk-taking
loci (Table S21). PRS analyses using the Clifton et al.
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summary statistics demonstrated consistent effects sizes,
but associations were attenuated (Tables S22-S26).
EQTL studies highlighted some genes of interest for
further biological investigation. At the Chr2 locus,
CGREF1, KHK and DPYSL5 are particularly implicated.
CGREF1 encodes a secretory protein involved in cell
adhesion and proliferation51,52. Despite its abundant
expression in the brain (Figure S5), its function remains
unexplored. KHK encodes ketohexokinase, an enzyme
involved in fructose metabolism. Although some studies
demonstrate fructose metabolism in the brain53,54,
another intriguing possibility is that KHK’s role in brain is
as a protein kinase55. DPYSL5, which encodes collapsin
response mediator protein (CRMP) 5, is involved in
neurogenesis, dendritic development and synaptic plasti-
city56,57. DPYSL5 null mice are viable and grossly nor-
mal57 and it will be of signiﬁcant interest to investigate
cognitive functions in these mice, given our ﬁndings and
impairments in learning and memory demonstrated for
other members of the CMRP family58. The Chr1 (women
only) lead SNP predicted expression of SDCCAG8, which
is involved in cortical development59 and mutations are
characterised by cognitive impairments60. At the Chr15,
we highlight C15orf59, which encodes a postsynaptic
density protein that regulates inhibitory neurotransmis-
sion and hippocampal excitability61. Taken together, our
eQTL analyses identiﬁed a number of candidate genes
involved in synaptic plasticity and neurogenesis. They also
emphasise the need to better understand the roles played
by CGREF1 and KHK in the brain. Finally, it is notable
that all the genes implicated by our eQTL analyses show
differential expression in the foetal versus adult brain,
emphasising the importance of considering their potential
impact on brain development, as well as their role in the
adult brain.
The lead Chr2 SNP shows evidence of selective and/or
differential associations with speciﬁc splice isoforms of
CGREF1 and KHK. This is notable given the evidence
suggesting that RNA splicing is a key mechanism med-
iating effects of disease-associated, non-coding variants,
including those linked with SCZ62. For CGREF1, although
multiple transcripts are annotated, the functional impact
of splicing is unknown. Functionally distinct splice iso-
forms of KHK have been reported63,64; however, the
junction/exon implicated by our eQTL analysis affects a
different region of the KHK gene (Table S16). Indeed, the
junction showing robust association with rs2304681
(which skips exons 2 and 3) is not present in any of the
currently annotated KHK transcripts. These ﬁndings
emphasise the importance of understanding the complete
transcript structure of genes relevant in the translation of
genomic ﬁndings into biological insights. In the case of
many (if not most) genes, the complement of splice iso-
forms present in human brain has been little explored65.
Our ﬁndings add further weight to the increasing body of
evidence66 suggesting that understanding isoform diver-
sity, and its regulation by cis-acting factors, will be critical
to unpick the biological impact of SNPs arising from
GWAS.
This study is comparable with those of most complex
traits investigated to date, both in terms of the risk
variants having only a small effect on risk-taking beha-
viour and the challenges for translating the ﬁndings into
biological mechanisms. Despite this, our ﬁndings con-
tribute substantial new knowledge on the biology of risk
taking and highlight several candidate genes for further
investigation. This work will stimulate future experi-
mental studies to elucidate our understanding of an
important but complex trait, which contributes to a very
broad range of adverse mental and physical health
outcomes.
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